BioMérieux: Invest Securities raises its target price.

(CercleFinance.com) - Invest Securities is maintaining "sell" rating on bioMérieux prior to the PAMA regulation in 2018 and the early return of tax on medical apparatus, although is inching up its target price from 129 euros to 143 euros, in the wake of sales estimates that have been increased by +2.
2%, +3.8% and +4.7% respectively for the years 2017 to 2019.

The broker's analysts underline that the publication of Q1 2017 sales (+13.7% like-for-like) reached a record and that the in vitro diagnostic specialist is thus significantly ahead of its annual guidance (+8%/+9%), which should be raised in H1 2017.

The analyst monitoring the stock continued, saying that over 2017, resistance forces (Virtuo, new tests FilmArray RP, PCT indications) that have recently been implemented should protect the growth of competition and boost market share.


Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.